Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873786 | 0.83 | GABRA1 (0.37) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL677730 | 0.80 | CA2 (0.33) | CYP1A2CYP2C9CA2ALDH1A1TYR | |
| SCHEMBL596305 | 0.79 | — | — | |
| SCHEMBL454798 | 0.79 | AR (0.31) | — | |
| SCHEMBL29084727 | 0.78 | CA2 (0.32) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL697788 | 0.76 | — | — | |
| SCHEMBL19356874 | 0.76 | — | — | |
| SCHEMBL3693116 | 0.74 | CA2 (0.30) | CA2 | |
| SCHEMBL3229140 | 0.74 | ALDH1A1 (0.48) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15319301 | 0.74 | CA2 (0.30) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | claimed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2020242960-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | claimed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-112449637-A | Benzothia (di) azepanes and their use as bile acid modulators | 阿尔比里奥公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2020242960-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-9585392-B2 | 3-phenylisoxazolin derivatives with herbicidal action | BAYER CROPSCIENCE AG (DE) | 2017-03-07 | — | — | US | disclosed |
| EP-0224024-B1 | SILANE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AGENTS CONTAINING THEM AND THEIR USE AS PESTICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-20 | — | — | EP | disclosed |
| US-4864027-A | INSECTICIDES, NEMATOCIDES, MITICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| US-4814340-A | 1,4-diaryl alkane derivatives having insecticidal and acaricidal activity | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-03-21 | — | — | US | disclosed |
| EP-0224024-A1 | Silane derivatives, process for their preparation, agents containing them and their use as pesticides | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-06-03 | — | — | EP | disclosed |
| US-4661501-A | Certain aryl-alkane-2-pyridyloxy-phenyl derivatives having insecticidal and acaricidal activity | MITSUI TOATSU CHEMICALS, INC. (JP) | 1987-04-28 | — | — | US | disclosed |
| US-4599362-A | 2-aryl-ethyl ether derivatives and insecticidal and acaricidal agents containing said derivatives | MITSUITOATSU CHEMICALS, INC. (JP) | 1986-07-08 | — | — | US | disclosed |
| US-4570005-A | REACTING THE ARYL PROPYL CHLORIDE WITH THE CORRESPONDING ARYL ALCOHOL OR ARYL MERCAPTAN | MITSUITOATSU CHEMICALS INC. (JP) | 1986-02-11 | — | — | US | disclosed |
| US-4397864-A | LOW TOXICITY | MITSUITOATSU CHEMICALS INC. (JP) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | HSP90B1, EIF4EBP1, SERPINA6 | GABRA1 3386/4885GABRB2 2207/4885CYP1A2 4794/4885 |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HSP90B1, EIF4EBP1, SERPINA6 | GABRA1 3386/4885GABRB2 2207/4885CYP1A2 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.